Day One Biopharmaceuticals Future Growth
Future criteria checks 2/6
Day One Biopharmaceuticals is forecast to grow earnings and revenue by 54.4% and 53.2% per annum respectively. EPS is expected to grow by 54.6% per annum. Return on equity is forecast to be -8.7% in 3 years.
Key information
54.4%
Earnings growth rate
54.6%
EPS growth rate
| Biotechs earnings growth | 23.2% |
| Revenue growth rate | 53.2% |
| Future return on equity | -8.7% |
| Analyst coverage | Good |
| Last updated | 25 Apr 2024 |
Recent future growth updates
Recent updates
Day One Pharmaceuticals: Ojemda Approval A Big Win, Current Valuation Fair
Apr 24We're Hopeful That Day One Biopharmaceuticals (NASDAQ:DAWN) Will Use Its Cash Wisely
Mar 18
Navigating Day One Biopharmaceuticals' Financial Health And Clinical Prospects
Feb 01We're Hopeful That Day One Biopharmaceuticals (NASDAQ:DAWN) Will Use Its Cash Wisely
Dec 04We're Not Very Worried About Day One Biopharmaceuticals' (NASDAQ:DAWN) Cash Burn Rate
Jun 19We're Hopeful That Day One Biopharmaceuticals (NASDAQ:DAWN) Will Use Its Cash Wisely
Mar 08Here's Why We're Not Too Worried About Day One Biopharmaceuticals' (NASDAQ:DAWN) Cash Burn Situation
Nov 22Day One Biopharmaceuticals: Recent Strong Data, And Major Catalysts Ahead
Sep 04Day One Biopharmaceuticals GAAP EPS of -$0.60
Aug 04Day One Biopharmaceuticals, Inc.'s (NASDAQ:DAWN) Intrinsic Value Is Potentially 52% Above Its Share Price
Jun 18Day One Biopharmaceuticals: Early Pediatric Brain Cancer Data Makes Tentative Buy Case
Jun 15We're Not Very Worried About Day One Biopharmaceuticals' (NASDAQ:DAWN) Cash Burn Rate
Apr 29An Intrinsic Calculation For Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Suggests It's 42% Undervalued
Jan 14Day One Biopharmaceuticals (NASDAQ:DAWN) Is In A Good Position To Deliver On Growth Plans
Dec 10Day One Biopharmaceuticals (NASDAQ:DAWN) Is In A Good Position To Deliver On Growth Plans
Aug 27Day One Biopharma draws bullish calls as quiet period ends
Jun 21Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 257 | -55 | -66 | 31 | 9 |
| 12/31/2025 | 86 | -177 | -185 | -110 | 10 |
| 12/31/2024 | 13 | -228 | -228 | -205 | 10 |
| 12/31/2023 | N/A | -189 | -150 | -147 | N/A |
| 9/30/2023 | N/A | -175 | -144 | -141 | N/A |
| 6/30/2023 | N/A | -166 | -127 | -127 | N/A |
| 3/31/2023 | N/A | -157 | -114 | -114 | N/A |
| 12/31/2022 | N/A | -142 | -110 | -110 | N/A |
| 9/30/2022 | N/A | -124 | -88 | -88 | N/A |
| 6/30/2022 | N/A | -105 | -77 | -77 | N/A |
| 3/31/2022 | N/A | -183 | -60 | -60 | N/A |
| 12/31/2021 | N/A | -171 | -57 | -49 | N/A |
| 9/30/2021 | N/A | -183 | -49 | -41 | N/A |
| 6/30/2021 | N/A | -167 | -41 | -33 | N/A |
| 3/31/2021 | N/A | -54 | -29 | -21 | N/A |
| 12/31/2020 | N/A | -41 | -14 | -13 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: DAWN is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: DAWN is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: DAWN is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: DAWN's revenue (53.2% per year) is forecast to grow faster than the US market (8.2% per year).
High Growth Revenue: DAWN's revenue (53.2% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: DAWN is forecast to be unprofitable in 3 years.